PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics
Acquisition Positions PainReform as a Potential Leader in High-Growth, High-Margin AI Solar Energy Management While Continuing Its Core Focus on Pharmaceutical Innovation Tel Aviv, Israel – March 5, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the successful closing […]
PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity
DeepSolar brings new customer base in creation, including major utility-scalesolar operators and independent power producers, whilebreaking into the residential solar market The Company remains committed to advancing its drug deliverytechnologies while broadening its growth potential Tel Aviv, Israel – February 18, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical […]
PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110
Tel Aviv, Israel – December 27, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced an update regarding its Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy. PainReform previously disclosed initial topline data from […]
PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial
Tel Aviv, Israel – November 20, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the receipt of partial topline data from its contract research organization (CRO), Lotus Clinical Research (“Lotus”), for the Phase 3 clinical trial evaluating PRF-110 in […]
PainReform Ltd. Confirms Sutures Compatibilityin Human Clinical Trials for PRF-110
Positive Compatibility Results Reinforce Safety and Efficacyof PRF-110 in Post-Surgical Pain Management Tel Aviv, Israel – September 11, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced positive findings regarding the compatibility of sutures in human clinical trials of its […]
PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds
TEL AVIV, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) — PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 989,300 ordinary shares of the […]
PainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy Procedures
PRF-110 Demonstrates Superior Coverage and Stability in Surgical Wounds Findings Highlight PRF-110’s Competitive EdgeOver Leading Pain Management Products Tel Aviv, Israel – August 21, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the successful determination of the optimal delivery […]
PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study
Tel Aviv, Israel – August 20, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced encouraging early safety results from its ongoing Phase 3 bunionectomy study of PRF-110, the Company’s proprietary post-surgical pain formulation. The study, which has now completed […]
PainReform Provides Business Update for the Second Quarter of 2024
Reaches full enrollment in the second part of Phase 3clinical trial of PRF-110 in bunionectomy Remains on track to announce top-line data in late 2024 New highly scalable manufacturing process expectedto significantly enhance future commercialization efforts Tel Aviv, Israel – August 15, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical […]
PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses
Tel Aviv, Israel – August 7, 2024 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced compelling safety data for its lead product candidate, PRF-110. This data, derived from pharmacokinetic (PK) studies in both herniorrhaphy and bunionectomy clinical trials, highlights PRF-110’s […]
